Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Pemphigus (OLE)
CTR20212085Phase 3Terminated
- Sponsor
- argenx
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in pemphigus vulgaris (PV), pemphigus foliaceus (PF), pemphigus, sponsored by argenx. Started Aug 2021; status: terminated.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)pemphigus
Beyond the preview
Go deeper on CTR20212085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212085.